logo
ResearchBunny Logo
Abstract
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and renal outcomes in patients with cardiovascular disease, chronic kidney disease (CKD), and heart failure (HF), regardless of type 2 diabetes (T2D) status. Their benefits extend beyond glucose reduction, encompassing effects on intraglomerular pressure, preload/afterload, potassium levels, left ventricular function, sympathetic nervous system activity, hematologic parameters, uric acid levels, and potentially anti-inflammatory properties. This review explores the multifaceted mechanisms underlying these cardiorenal benefits.
Publisher
Journal of Clinical Medicine
Published On
Apr 12, 2023
Authors
A Rastogi, James L Januzzi Jr
Tags
SGLT2 inhibitors
cardiovascular diseases
chronic kidney disease
heart failure
type 2 diabetes
mechanisms
renal outcomes

Related Publications

Explore these studies to deepen your understanding of the subject.

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Medicine and Health

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

J. F. E. Mann, P. Rossing, et al.

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
Medicine and Health

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

N. Snelder, R. Heinig, et al.

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Medicine and Health

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

H. M. Colhoun, I. Lingvay, et al.

Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial
Medicine and Health

Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial

A. Podadera-herreros, A. P. A. Larriva, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny